205 related articles for article (PubMed ID: 18779616)
1. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Saarto T; Vehmanen L; Blomqvist C; Elomaa I
J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
[TBL] [Abstract][Full Text] [Related]
2. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
[TBL] [Abstract][Full Text] [Related]
3. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
[TBL] [Abstract][Full Text] [Related]
4. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.
McCloskey E; Paterson A; Kanis J; Tähtelä R; Powles T
Eur J Cancer; 2010 Feb; 46(3):558-65. PubMed ID: 20031392
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
6. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
[TBL] [Abstract][Full Text] [Related]
7. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients.
Saarto T; Vehmanen L; Virkkunen P; Blomqvist C
Acta Oncol; 2004; 43(7):650-6. PubMed ID: 15545185
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
11. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
[TBL] [Abstract][Full Text] [Related]
13. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
[TBL] [Abstract][Full Text] [Related]
14. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
Diel IJ; Solomayer EF; Costa SD; Gollan C; Goerner R; Wallwiener D; Kaufmann M; Bastert G
N Engl J Med; 1998 Aug; 339(6):357-63. PubMed ID: 9691101
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
16. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.
Floreani A; Carderi I; Ferrara F; Rizzotto ER; Luisetto G; Camozzi V; Baldo V
Dig Liver Dis; 2007 Jun; 39(6):544-8. PubMed ID: 17416215
[TBL] [Abstract][Full Text] [Related]
17. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
18. Clodronate treatment of established bone loss in cardiac recipients: a randomized study.
Ippoliti G; Pellegrini C; Campana C; Rinaldi M; D'Armini A; Goggi C; Aiello M; Viganò M
Transplantation; 2003 Feb; 75(3):330-4. PubMed ID: 12589153
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Brufsky A; Harker WG; Beck JT; Carroll R; Tan-Chiu E; Seidler C; Hohneker J; Lacerna L; Petrone S; Perez EA
J Clin Oncol; 2007 Mar; 25(7):829-36. PubMed ID: 17159193
[TBL] [Abstract][Full Text] [Related]
20. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
Sato S; Takada T; Katsuki Y; Kimura N; Kaneko Y; Suwa A; Hirakata M; Kuwana M
J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
